s6y

BGM Group Ltd.

Ticker
BGM
CIK
1779578
Industry
Pharmaceutical Preparations
Formerly
Qilian International Holding Group, Qilian International Holding Group Ltd

Financials 4

  1. NT 20-F Notice under Rule 12b25 of inability to timely file all or part of an annual report of form 20-F for period ending Sep 30, 2025
  2. NT 20-F Notice under Rule 12b25 of inability to timely file all or part of an annual report of form 20-F for period ending Sep 30, 2023
  3. NT 20-F Notice under Rule 12b25 of inability to timely file all or part of an annual report of form 20-F for period ending Sep 30, 2022
  4. NT 20-F Notice under Rule 12b25 of inability to timely file all or part of an annual report of form 20-F for period ending Sep 30, 2021

Ownership 11

  1. 3 Initial statement of beneficial ownership of securities
  2. 3 Initial statement of beneficial ownership of securities
  3. 3 Initial statement of beneficial ownership of securities
  4. 3 Initial statement of beneficial ownership of securities
  5. 3 Initial statement of beneficial ownership of securities
  6. SC 13D Major Shareholders
  7. SC 13D/A Major Shareholders
  8. SC 13D Major Shareholders
  9. SC 13G Major Shareholders
  10. SC 13G Major Shareholders

All 11 ownership filings

Prospectus 10

  1. S-8 Initial registration statement for securities to be offered to employees pursuant to employee benefit plans
  2. S-8 Initial registration statement for securities to be offered to employees pursuant to employee benefit plans
  3. 424B4 Prospectus filed pursuant to Rule 424(b)(4)
  4. FWP Filing under Securities Act Rules 163/433 of free writing prospectuses
  5. FWP Filing under Securities Act Rules 163/433 of free writing prospectuses
  6. FWP Filing under Securities Act Rules 163/433 of free writing prospectuses
  7. FWP Filing under Securities Act Rules 163/433 of free writing prospectuses
  8. DRS/A Draft registration statement submitted by Emerging Growth Company under Securities Act Section 6(e) or by Foreign Private Issuer under Division of Corporation Finance policy
  9. DRSLTR Correspondence Related to Draft Registration Statement
  10. DRS Draft registration statement submitted by Emerging Growth Company under Securities Act Section 6(e) or by Foreign Private Issuer under Division of Corporation Finance policy

Other 129

  1. 6-K Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments
  2. 6-K Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments
  3. 6-K Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments
  4. 6-K Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments
  5. 6-K Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments
  6. 6-K Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments
  7. 20-F Annual and transition report of foreign private issuers pursuant to Section 13 or 15(d)
  8. 6-K Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments
  9. 6-K Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments
  10. 6-K Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments

All 129 other filings